Ahead of appearing at the Spark+ Australian Equities Day in Singapore, PharmAust’s (ASX:PAA) Managing Director Dr Michael Thurn speaks with The Stock Network’s Lel Smits about:
🧬 A re-prioritised commercialisation strategy: PharmAust focus on neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s disease
🧬 Monepantel gets US FDA Orphan Drug Designation for treatment of ALS:
Next steps following PharmAust’s Monepantel recently granted Orphan Drug Designation for the treatment of ALS by the US FDA
Watch the full interview ⚡️ https://youtu.be/VJkvSG3bkrA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697